×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen Names Thomas Flanagan Senior Vice President and Chief Information Officer

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 20, 2006--Amgen (NASDAQ:AMGN), the world's leading biotechnology company, today announced the appointment of Thomas Flanagan as senior vice president and chief information officer (CIO). Flanagan replaces Hassan Dayem, who is retiring.

Flanagan joined Amgen in June 2004 as vice president, Information Systems, and has been leading Amgen's global enterprise resource planning program (ERP) since February 2005. Prior to joining Amgen, Flanagan spent eight years at MCI, where he served in a variety of executive capacities including CIO and senior vice president of Global Service Delivery. Before joining MCI in December 1995, he spent 24 years as an officer in the United States Navy.

Dayem joined Amgen in May 2002. Prior to his Amgen appointment, he served as vice president, Information Services and CIO at Merck & Co. Before joining Merck, Dayem served in a number of positions at Los Alamos National Laboratory, including division director, Computing Information and Communications division.

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

EDITOR'S NOTE: An electronic version of this news release may be accessed via our Web site at www.amgen.com. Journalists and media representatives may sign up to receive all news releases electronically at time of announcement by filling out a short form in the Media section of the Web site.

CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Cory Rivera, 805-447-1060 (investors)

SOURCE: Amgen